When cancer patients undergo chemotherapy, the dose of most drugs is calculated based on the patient's body surface area. This is estimated by plugging the patient's height and weight into an equation, dating to 1916, that was formulated from data on just nine patients ..read more

Mayo Clinic researchers have used a new approach to chemotherapy to more than double the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer that has spread to the lining of the abdominal cavity, according to a study published in the Annals of Surgical Oncology ..read more

In a study of patients who smoked when they were diagnosed with laryngeal cancer, those who quit smoking before starting chemotherapy or radiation responded better to treatment, were less likely to need their voice boxes surgically removed, and lived significantly longer than those who continued to smoke. The research, from the University of Oklahoma, is published in the journal Otolaryngology-Head and Neck Surgery ..read more

The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC ..read more

For patients with locally advanced prostate cancer, combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen (PSA) levels, compared to hormonal therapy alone, according to a study in the April issue of the Journal of Urology ..read more

Researchers at Peter Mac have found a new way to treat a form of leukemia that stops the disease in its tracks to prolong remission ..read more

Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue of the New England Journal of Medicine ..read more

For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego ..read more

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, including those with PD-L1-low tumors, compared with chemotherapy alone, according to results from the phase III COMPASSION-15 trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5–10 ..read more

Recent progress in research related to cancer treatment has made it possible for children with cancer to survive into adulthood. However, the long-term physiological consequences of chemotherapy are understudied ..read more